| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Parthenolide | CTRPv2 | pan-cancer | AAC | 0.05 | 0.2 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | 0.039 | 0.2 |
| mRNA | navitoclax:piperlongumine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.047 | 0.2 |
| mRNA | WZ8040 | CTRPv2 | pan-cancer | AAC | 0.05 | 0.2 |
| mRNA | SR1001 | CTRPv2 | pan-cancer | AAC | -0.049 | 0.2 |
| mRNA | lenalidomide | GDSC1000 | pan-cancer | AAC | -0.048 | 0.2 |
| mRNA | QL-X-138 | GDSC1000 | pan-cancer | AAC | 0.041 | 0.2 |
| mRNA | AS605240 | GDSC1000 | pan-cancer | AAC | 0.043 | 0.2 |
| mRNA | GSK269962A | GDSC1000 | pan-cancer | AAC | 0.042 | 0.2 |
| mRNA | GNF-2 | GDSC1000 | pan-cancer | AAC | 0.072 | 0.2 |